Tonix Pharmaceuticals Holding Corp

Tonix Pharmaceuticals CEO buys 15,000 shares, signaling confidence amid preclinical oncology data and a bullish insider‑buying trend that could boost valuation.

Tonix insider option purchases signal confidence as CNS drug pipeline—TNX‑102 & TNX‑201—faces FDA review; investors should track clinical milestones and regulatory decisions for potential upside.